StocksMedium•9 October 2026•
1 min read
FDA Approves Roche's Tecentriq for Stage III Colon Cancer Treatment
Key Facts
1The US FDA approved Roche’s Tecentriq in combination with chemotherapy for the adjuvant treatment of stage III dMMR colon cancer.
2Results from the ATOMIC study showed Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone.
The US Food and Drug Administration approved Roche’s Tecentriq in combination with chemotherapy for the adjuvant treatment of stage III dMMR colon cancer. GlobeNewswire reported that the approval establishes a new treatment option for patients with this specific genetic profile, marking the 12th FDA indication for the immunotherapy drug.
Results from the ATOMIC study demonstrated that the combination therapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. Regarding market performance, RHHVF closed at $425.78 on October 8, 2026, having traded between a day low of $422.31 and a high of $433.24 during that session.